Solstice Advanced Materials heads into October with a striking divergence: short sellers are retreating rapidly while options traders have swung to their most bullish posture in months, even as the stock itself slides.
The short-side story has moved decisively in one direction. Short interest fell by more than a third over the past week, dropping from roughly 8.5 million shares to 5.4 million, and is now down 57% from its late-August peak of more than 15 million shares. At 3.4% of free float, the position is modest by any measure. The lending market reinforces that picture: availability is essentially unlimited, with shares-available-to-borrow running at more than 9,000% of current short interest, meaning there is no scarcity pressure in the borrow pool whatsoever. Cost to borrow has collapsed in tandem, falling 36% on the week to just 0.27%, a negligible rate that signals no meaningful demand to establish new short positions. The ORTEX short score of 32 puts SOLS well into the lower half of the universe on short pressure.
Options positioning tells a contrasting story. The put/call ratio dropped sharply to 0.77 on Tuesday, nearly three and a half standard deviations below its 20-day average of 0.98. That is an unusually large swing toward calls relative to recent norms, and it arrives against a backdrop where the ratio was sitting above 1.5 as recently as late August, when the stock was under heavier short pressure. The 52-week range for the PCR runs from zero to 4.78, which gives some context for how wide the swings can be, but Tuesday's reading is the most call-skewed the options market has been in the recent window. Whether that reflects genuine conviction or short-term hedging unwind is harder to say, but the direction is unambiguous.
The valuation backdrop offers some structural grounding. SOLS trades at a PE of 17.3 and an EV/EBITDA of 9.6, both of which have drifted lower over the past month as the stock has given back 12% to close at $56.01. The price-to-book sits at 4.1. These are not cheap multiples for a specialty chemicals name, but they are compressing. The largest institutional holder is BlackRock, which last disclosed a 9.4% stake in July, up from 8.1% previously. Vanguard entities collectively hold another 10% or so across multiple funds, though the picture here is complicated: the Vanguard Group filed a 13G/A in March disclosing a drop to 0% from 11.58%, while separate Vanguard subsidiary vehicles have since filed their own 13G disclosures above 5%. Stakes are as-last-disclosed and holders dropping below 5% may not file again, so the precise current picture requires some caution.
On the insider side, all recent transactions are compensation-related: option exercises paired with tax-withholding sales by SVP-level executives in late July and early August. These are mechanical in nature, not discretionary buying or selling, and carry no signal on management's view of the stock.
SOLS reports next on October 30. The most interesting thing to watch between now and then is whether the options skew toward calls persists or reverts as the earnings date approaches, and whether the short interest decline stabilises around current levels or continues unwinding the elevated position built through August.
See the live data behind this article on ORTEX.
Open SOLS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
